Business
Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs Site in Korea
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced a collaboration agreement with Eli Lilly and Company (Lilly) to establish a Lilly Gateway Labs (LGL) site in Korea.
About this update from Samsung Biologics Co., Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Partnership expands Lilly's global network of shared innovation hubs and strengthens Samsung Biologics' role as a connector between early-stage innovation and global development and manufacturing","length":203,"tagName":"p"}]},{"val":[{"type":"text","content":"Facility to provide research infrastructure for up to 30 biotech companies within Samsung Biologics' Bio Campus II to support the advancement of next-generation therapies","length":174,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":377,"olType":false},{"type":"text","content":"INCHEON, South Korea, March 10, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced a collaboration agreement with Eli Lilly and Company (Lilly) to establish a Lilly Gateway Labs (LGL) site in Korea.","length":284,"tagName":"p"},{"type":"image","alt":"Samsung Biologics Logo (PRNewsfoto/Samsung Biologics)","displaySize":"","headline":null,"caption":"Samsung Biologics Logo (PRNewsfoto/Samsung Biologics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/35fb5e8461f86f1d8888f5be2870db4d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U0uYbfpMO6X0VuS3bLn6JQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/35fb5e8461f86f1d8888f5be2870db4d","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2395686/Samsung_Biologics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The new Gateway Labs site will serve as a hub to support early-stage and emerging biotechnology companies, as they advance scientific research toward development and manufacturing. The facility will feature flexibly designed laboratory space and research infrastructure, collaborative space, and operational support, with capacity for up to 30 companies jointly selected by Lilly and Samsung.","length":392,"tagName":"p"},{"type":"text","content":"Under the collaboration agreement, Samsung Biologics will develop and operate the new facility, with Lilly Gateway Labs providing customized scientific engagement to support resident biotech companies and catalyze collaboration across the Korea life sciences sector. Located within Samsung ...